\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区
^{[1] <\/sup>Apfelbacher C, Bewley A, Molin S, et al. Prevalence of Chronic Hand Eczema in adults: A cross-sectional multi-national study of 60,000 respondents in the general population. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[2] <\/sup>Ther Clin Risk Manag. 2020 Dec 31;16:1319-1332.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[3] <\/sup>Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[4]<\/sup> ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1). Identifier: NCT04871711. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04872101.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[5]<\/sup> ClinicalTrials.gov. National Library of Medicine (U.S.). Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2). Identifier: NCT04872101. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04872101.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[6]<\/sup> Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet 2024; published online July 18. https:\/\/doi.org\/10.1016\/S0140-6736(24)01027-<\/span><\/p> <\/td> \n <\/tr> \n}
^{[7] <\/sup>ClinicalTrials.gov. National Library of Medicine (U.S.). Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials (DELTA3). Identifier: NCT04949841 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04949841<\/span><\/p> <\/td> \n <\/tr> \n}
^{[8] <\/sup>Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet 2024; published online July 18. https:\/\/doi.org\/10.1016\/S0140-6736(24)01027-4..<\/span><\/p> <\/td> \n <\/tr> \n}
^{[9]<\/sup> Schliemann S, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: results of the Phase 3 DELTA 2 trial. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023. Berlin, Germany. 11– 14 October. Poster Presentation #P0395.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[10]<\/sup> Bissonnette R, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: results of the Phase 3 DELTA 1 trial. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023. Berlin, Germany. 11– 14 October. Poster Presentation #P0369.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[11] <\/sup>Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[12] <\/sup>Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[13]<\/sup> Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360<\/span><\/p> <\/td> \n <\/tr> \n}
^{[14]<\/sup> Diepgen TL, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015 Jan;13(1):e1–22.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[15] <\/sup>Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[16]<\/sup> Apfelbacher C, Bewley A, Molin S, et al. Prevalence of Chronic Hand Eczema in adults: A cross-sectional multi-national study of 60,000 respondents in the general population. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3<\/span><\/p> <\/td> \n <\/tr> \n}
^{[17] <\/sup>Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[18] <\/sup>Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[19]<\/sup> Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[20]<\/sup> Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n}
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>